Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.54 |
| ▸ | RARA | P10276 | 3/20 | 0.54 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
| ▸ | RARG | P13631 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451958 | 0.92 | GCK (0.65) | GCKRARARARBRARG | |
| SCHEMBL2651412 | 0.91 | GCK (0.63) | GCKRARARARBRARG | |
| SCHEMBL2650016 | 0.86 | GCK (0.58) | GCKRARARARBRARG | |
| SCHEMBL2651052 | 0.86 | GCK (0.57) | GCKRARARARBRARG | |
| SCHEMBL5421905 | 0.85 | GCK (0.58) | GCKRARARARBRARGNPC1 | |
| SCHEMBL9071663 | 0.83 | GCK (0.53) | GCKRARARARBRARGNPC1 | |
| SCHEMBL2666296 | 0.82 | GCK (0.77) | GCKRARARARBRARG | |
| SCHEMBL14190698 | 0.78 | GCK (0.59) | GCKRARARARBRARG | |
| SCHEMBL2652506 | 0.78 | GCK (0.81) | GCKRARARARBRARG | |
| SCHEMBL5419201 | 0.77 | GCK (0.68) | GCKRARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB | 2007-05-17 | — | — | US | disclosed |
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB | 2007-05-17 | — | — | US | disclosed |
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB | 2007-05-17 | — | — | US | disclosed |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1404335-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | Astrazeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000267-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000267-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | GCK 1/4885RARA 3103/4885RARB 3070/4885 |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | GCK 1/4885RARA 2675/4885RARB 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.